Weight-loss drug Ozempic launched at Rs 8,800 a month
A once-week injection is approved in India for adults with uncontrolled type 2 diabetes, along with diet and exercise
image for illustrative purpose
New Delhi: Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four weeks.
Ozempic -- a once-weekly injectable formulation of semaglutide -- is approved in India for adults with uncontrolled type 2 diabetes, along with diet and exercise.
The drug is available in three dosage forms -- 0.25mg, 0.5 mg, and 1mg -- in a single-use pre-filled pen called Novofine Needles designed for painless subcutaneous injection, the drug maker said.
The 0.25 mg, which is the initial dose, is priced at Rs 8,800, followed by Rs10,170 for 0.5 mg and Rs 11,175 for 1 mg. Each pen contains four weekly doses.
“Bringing Ozempic to India is a major milestone. Backed by global trust, proven clinical excellence, and world-class quality, reinforced by a robust supply chain, Ozempic offers Indian doctors an effective treatment choice,” said Vikrant Shrotriya, Managing Director, Novo Nordisk India. “Our goal is to provide patients with an innovative and accessible therapy that offers improved glycaemic control, meaningful weight management," Shrotriya added.
